(HealthDay)—Switching dual antiplatelet therapy (DAPT) from aspirin plus ticagrelor or prasugrel to aspirin plus clopidogrel after acute coronary syndrome (ACS) provides benefits regardless of initial platelet reactivity, ...
Dec 20, 2017
0
4
(HealthDay)—High-sensitivity troponin (hsTnT) assay can identify patients presenting with suspected acute coronary syndrome at very low risk for 30-day adverse cardiac events (ACE), according to a study published online ...
Dec 14, 2017
0
4
(HealthDay)—Cardiovascular disease (CVD) hospitalization rates have declined in recent years among individuals with and those without diabetes, according to a study published online Nov. 17 in Diabetes Care.
Nov 28, 2017
0
0
(HealthDay)—High-sensitivity cardiac troponin I concentration can identify individuals at low risk of myocardial infarction or cardiac death within 30 days among patients with suspected acute coronary syndrome, according ...
Nov 13, 2017
0
0
When women participate in a medical research paper, that research is more likely to take into account the differences between the way men and women react to diseases and treatments, according to a new study by Stanford researchers.
Nov 7, 2017
0
1
(HealthDay)—Patients with a CYP2C19 loss-of-function allele have increased risk of major adverse cardiovascular events (MACE) with clopidogrel versus alternative antiplatelet therapy after percutaneous coronary intervention ...
Nov 3, 2017
0
0
A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests that statins are having a positive impact, according to an observational study in nearly 49 000 patients presented at the ASEAN Federation ...
Nov 3, 2017
0
11
Elderly patients undergoing PCI often receive bare-metal stents (BMS) instead of drug-eluting stents (DES) to shorten the duration of dual antiplatelet therapy (DAPT) and reduce bleeding risk. However, results from the SENIOR ...
Nov 2, 2017
0
0
Results from the prospective, multicenter, randomized investigator-initiated REDUCE trial were reported today at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular ...
Nov 2, 2017
0
0
Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting bioresorbable vascular scaffold (BVS) trial to date, found BVS to be noninferior to a cobalt-chromium everolimus-eluting stent (CoCr-EES) for target ...
Nov 1, 2017
0
0
